| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/14/2013 | US20130064880 Administration regime for n-hydroxy-4-benzamide |
| 03/14/2013 | US20130064879 Compositions and Methods for Inhibiting Viral Replication |
| 03/14/2013 | US20130064878 Wound healing compositions and methods |
| 03/14/2013 | US20130064877 Composition for the transdermal delivery of fentanyl |
| 03/14/2013 | US20130064874 Method for producing orally administrable edible agent of aggregated substance-containing laminate film form and orally administrable edible agent of aggregated substance-containing laminate film form |
| 03/14/2013 | US20130064870 Dry powder inhalation composition |
| 03/14/2013 | US20130064865 Therapy to reduce extravasation damage |
| 03/14/2013 | US20130064858 Polysaccharide suitable to modulate immune response |
| 03/14/2013 | US20130064855 Reprogramming immune environment in breast cancer via dendritic cells |
| 03/14/2013 | US20130064847 Treatment and Composition for Achieving Skin Anti-Aging Benefits by Corneum Protease Activation |
| 03/14/2013 | US20130064839 Method of rapidly producing improved vaccines for animals |
| 03/14/2013 | US20130064835 Rage regulates rock activity in cardiovascular disease |
| 03/14/2013 | US20130064833 Monitoring and Modulating HGF/HGFR Activity |
| 03/14/2013 | US20130064827 Il-17 homologous polypeptides and thereapeutic uses thereof |
| 03/14/2013 | US20130064820 Methods and compositions for treating degos' disease |
| 03/14/2013 | US20130064816 TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE |
| 03/14/2013 | US20130064815 Inducing apoptosis in quiescent cells |
| 03/14/2013 | US20130064814 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| 03/14/2013 | US20130064812 Combination therapies for hematologic malignancies |
| 03/14/2013 | US20130064810 Methods and Compositions for the Detection and Treatment of Cancer involving miRNAs and miRNA Inhibitors and Targets |
| 03/14/2013 | US20130064808 Biologically Active Oils |
| 03/14/2013 | US20130064806 Novel pharmaceutical salts and polymorphs of a factor xa inhibitor |
| 03/14/2013 | US20130064794 Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections |
| 03/14/2013 | US20130064793 Compounds and pharmaceutical compositions for the treatment of viral infections |
| 03/14/2013 | US20130064790 Peptides with the capacity to bind to interleukin-10 (il-10) |
| 03/14/2013 | US20130064789 Hairy Cell Leukemia Biomarkers and Methods of Using Same |
| 03/14/2013 | US20130064786 siRNA HYDROGEL AND METHOD FOR MANUFACTURING THE SAME |
| 03/14/2013 | US20130064783 Boron-containing small molecules |
| 03/14/2013 | US20130064780 Compositions comprising avermectin/azelaic acid compounds useful for treating e.g., rosacea |
| 03/14/2013 | US20130064775 Use of riluzole for treating or preventing the adverse effects of antineoplastic agents |
| 03/14/2013 | US20130064774 Methods and compositions for maintenance of a functional wound |
| 03/14/2013 | US20130064773 Drug-containing implants and methods of use thereof |
| 03/14/2013 | DE102011113059A1 Therapeutische Anwendungen von Ectoin Therapeutic applications of ectoine |
| 03/14/2013 | CA2861150A1 Morphinan derivative |
| 03/14/2013 | CA2854206A1 A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof |
| 03/14/2013 | CA2849423A1 Silicone coated implants |
| 03/14/2013 | CA2848212A1 Neuroactive steroids, compositions, and uses thereof |
| 03/14/2013 | CA2848148A1 Benzonitrile derivatives as kinase inhibitors |
| 03/14/2013 | CA2848129A1 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators |
| 03/14/2013 | CA2848038A1 Antioxidant formulations |
| 03/14/2013 | CA2848012A1 Methods for treating intrapulmonary infections |
| 03/14/2013 | CA2848010A1 Therapeutic applications of ectoine |
| 03/14/2013 | CA2848009A1 Anti-inflammatory compositions comprising malvidin - 3 - o - beta-glucoside and a propolis extract |
| 03/14/2013 | CA2847817A1 Treating cough and tussive attacks |
| 03/14/2013 | CA2847811A1 Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
| 03/14/2013 | CA2847810A1 Pharmaceutical combination comprising a cip2a silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function |
| 03/14/2013 | CA2847736A1 A new polymorphic form of pridopidine hydrochloride |
| 03/14/2013 | CA2847726A1 The mirna-212/132 family as a therapeutic target |
| 03/14/2013 | CA2847624A1 Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof |
| 03/14/2013 | CA2847563A1 Amido compounds as ror.gamma.t modulators and uses thereof |
| 03/14/2013 | CA2847514A1 Amino-substituted imidazopyridazines |
| 03/14/2013 | CA2847339A1 Piperazine-substituted benzothiophene derivatives as antipsychotic agents |
| 03/14/2013 | CA2847019A1 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| 03/14/2013 | CA2847011A1 Scheme for administering n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide |
| 03/14/2013 | CA2846898A1 Retinal cyclodextrin acetals and hemiacetals for clarifying skin complexion |
| 03/14/2013 | CA2846884A1 Pharmaceutical compositions comprising an aromatase inhibitor |
| 03/14/2013 | CA2846503A1 Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy |
| 03/14/2013 | CA2846299A1 Oral suspension |
| 03/14/2013 | CA2846275A1 Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| 03/14/2013 | CA2845929A1 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
| 03/14/2013 | CA2845766A1 Benzothiazolone compound |
| 03/14/2013 | CA2845380A1 Crystalline forms of cabazitaxel |
| 03/14/2013 | CA2844652A1 Pde10 modulators |
| 03/14/2013 | CA2844175A1 Lipophilic dopamine derivatives and their use |
| 03/13/2013 | EP2567966A1 Novel ecdysterone synthesis derivative, preparation method and use thereof |
| 03/13/2013 | EP2567963A1 Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| 03/13/2013 | EP2567960A2 Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis |
| 03/13/2013 | EP2567959A1 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| 03/13/2013 | EP2567958A1 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals |
| 03/13/2013 | EP2567957A1 Compounds for the treatment of dyslipidemia and related diseases |
| 03/13/2013 | EP2567956A1 Novel prenylarene compound and use thereof |
| 03/13/2013 | EP2567955A2 Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| 03/13/2013 | EP2567954A1 Method for inhibiting tau protein aggregation and treatment of alzheimer's disease with a compound derived from quinoline |
| 03/13/2013 | EP2567950A1 Substituted alkine derivatives as anti-cancer agents |
| 03/13/2013 | EP2567710A1 Aqueous pharmaceutical system for the administration of drugs to the nails |
| 03/13/2013 | EP2567705A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 03/13/2013 | EP2567701A2 Treatment of heart failure in non-human mammals with an aldosterone antagonist |
| 03/13/2013 | EP2567700A1 Vitamin-containing nutrition infusion for administration through peripheral vein |
| 03/13/2013 | EP2567699A1 Treatment of progressive neurodegenerative disease with ibudilast |
| 03/13/2013 | EP2567698A1 GPR 17 agonists and screening assay |
| 03/13/2013 | EP2567697A1 Topical pharmaceutical compositions |
| 03/13/2013 | EP2567696A1 Compositions for treating autism spectrum disorder |
| 03/13/2013 | EP2567695A1 Antioxidant composition for reducing oxidative stress ascribable to treatment with hormonal contraceptives |
| 03/13/2013 | EP2567694A2 Non-cariogenic material and cariostatic agent containing rare sugars |
| 03/13/2013 | EP2567691A1 Aqueous compositions comprising arbekacin |
| 03/13/2013 | EP2567690A1 The use of amisulpride as an anti-emetic |
| 03/13/2013 | EP2567689A1 Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| 03/13/2013 | EP2567625A1 Preparation containing betulinic acid, obtained from a plant of the family Marcgraviaceae |
| 03/13/2013 | EP2567618A1 Pharmaceutical composition containing an N-phenylpyrazole derivative, use for the preparation of a topical veterinary drug for flea control |
| 03/13/2013 | EP2567225A2 Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders |
| 03/13/2013 | EP2566967A1 Detection and treatment of fibrosis |
| 03/13/2013 | EP2566877A1 Methods of reducing symptoms in subjects using single dosage forms with tapering release rates |
| 03/13/2013 | EP2566876A1 Methods and compounds for inhibiting glycosyltransferases |
| 03/13/2013 | EP2566872A1 Compounds for the treatment of hepatitis c |
| 03/13/2013 | EP2566870A1 New pro-drugs of amaryllidaceae isocarbostyril products and their use against brain tumors |
| 03/13/2013 | EP2566869A1 Pyridone and aza-pyridone compounds and methods of use |
| 03/13/2013 | EP2566868A1 Pyrrolo [3, 2 -d]pyrimidin-3 -yl derivatives used as activators of ampk |
| 03/13/2013 | EP2566867A1 Pyrazole compounds as jak inhibitors |
| 03/13/2013 | EP2566866A1 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| 03/13/2013 | EP2566864A2 Pyridazinones as gpr119 agonists |